Andrx enters into agreement with Pfizer
Andrx Corporation, of Fort Lauderdale, FL, US, has entered into agreements with Pfizer and Alza Corporation to resolve patent infringement litigation involving the Company's pending Abbreviated New Drug Application (ANDA) for bioequivalent versions of Glucotrol XL (extended release glipizide) 10 mg, 5 mg and 2.5 mg extended release tablets.
Andrx Corporation, of Fort Lauderdale, FL, US, has entered into agreements with Pfizer and Alza Corporation to resolve patent infringement litigation involving the Company's pending Abbreviated New Drug Application (ANDA) for bioequivalent versions of Glucotrol XL (extended release glipizide) 10 mg, 5 mg and 2.5 mg extended release tablets.
Pfizer and Alza have agreed to dismiss their lawsuits against Andrx and all parties have executed mutual releases of any and all related claims. The settlement is subject to court approval. Pursuant to the agreement, Andrx will receive a royalty-bearing sublicense under relevant Alza patents, under which it will be able to manufacture and market products under its ANDA.
Additionally, commencing no later than January 1, 2004, Pfizer has also agreed to supply Andrx with all or any strength of Pfizer's product, for sale by Andrx as an authorized generic under Pfizer's New Drug Application. Glucotrol XL had US sales of approximately $320m in 2002, according to IMS data.